Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer

Huayi Li, Zikun Peng, Jianqing Zhu, Weidong Zhao, Yi Huang, Ruifang An, Hong Zheng, Pengpeng Qu, Li Wang, Qi Zhou, Danbo Wang, Ge Lou, Jing Wang, Ke Wang, Beihua Kong, Xing Xie, Rutie Yin, John Low, Abdul Malik Rozita, Lim Chun Sen, Yong Chee Meng,Kho Swee Kiong, Jihong Liu, Zhiqing Liang, Weiguo Lv, Yaping Zhu, Weiguo Hu, Wei Sun, Jingya Su, Qiqi Wang, Rongyu Zang, Ding Ma, Qinglei Gao

BMC Medicine（2024）

Cited 1|Views36

No score

Abstract

The prospective phase III multi-centre L-MOCA trial (NCT03534453) has demonstrated the encouraging efficacy and manageable safety profile of olaparib maintenance therapy in the Asian (mainly Chinese) patients with platinum-sensitive relapsed ovarian cancer (PSROC). In this study, we report the preplanned exploratory biomarker analysis of the L-MOCA trial, which investigated the effects of homologous recombination deficiency (HRD) and programmed cell death ligand 1 (PD-L1) expression on olaparib efficacy. HRD status was determined using the ACTHRD assay, an enrichment-based targeted next-generation sequencing assay. PD-L1 expression was assessed by SP263 immunohistochemistry assay. PD-L1 expression positivity was defined by the PD-L1 expression on ≥ 1

Translated text

Key words

Platinum-sensitive relapsed ovarian cancer,Olaparib,PD-L1 expression,BRCA1/2,PARP inhibitors,Homologous recombination deficiency,L-MOCA trial,Biomarker

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined